CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In truth, the launch of the Company's new product, Inspire V, was a disaster because demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment. Moreover—and contrary to defendants' statements assuring investors that Inspire had taken all necessary steps to ensure a successful launch and, later, that the launch was in fact p ...

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that negatively impacted investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong customer demand visibility, the company faced a sustained decline in sales for two of its electrophysiology devices [2]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio & vascular segment, leading to misleading positive statements about its business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Insights - Autonomix Medical, Inc. is focused on advancing precision nerve-targeted treatments and has recently participated in a Virtual Investor CEO Connect segment [2][3] - The CEO, Brad Hauser, highlighted two main priorities: strengthening intellectual property protection and exploring applications beyond pancreatic cancer, including cardiovascular, pulmonary, and interventional pain management [3] Company Overview - Autonomix is a medical device company that aims to revolutionize the diagnosis and treatment of diseases involving the nervous system through innovative technologies [4] - The company's platform technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Technology and Applications - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5] - The platform is still investigational and has not yet received marketing clearance in the United States [5]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. - The company had previously claimed strong sales growth and market position for its EP devices, which is now being challenged [4]. Group 3: Financial Performance - Integer lowered its 2025 sales guidance to a range of $1.840 billion to $1.854 billion, down from $1.850 billion to $1.876 billion, which is below analysts' expectations [6]. - The company anticipates poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [6]. - Following the announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6][5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, but failed to prepare clinicians and payors, leading to significant delays and weak demand [5][6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspira Technologies has reaffirmed binding purchase orders totaling $49.5 million, with payment activities set to commence in the 2026 fiscal cycle, aligning with regulatory and deployment milestones [1][2]. Group 1: Purchase Orders and Execution - The company confirmed that the purchase orders remain valid and the distributor plans to advance these orders during 2026 [2]. - The payment framework for the binding purchase orders is structured to align with the company's revenue recognition framework, starting in the 2026 fiscal cycle [2][4]. - The updated schedule reflects necessary regulatory sequencing and technical implementation requirements, which are standard for large-scale healthcare deployments [3]. Group 2: Coordination and Risk Management - Inspira is actively coordinating with distribution partners, regulators, and funding organizations to advance execution milestones and finalize delivery schedules [4]. - This alignment aims to reduce execution risk, enhance operational visibility, and support a phased rollout across target markets [4]. - The company expects to provide updates regarding upcoming execution and deployment milestones [4]. Group 3: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [5]. - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake [5]. - Inspira is also advancing the HYLA™ blood sensor platform, which offers continuous, non-invasive monitoring, positioning the company as an attractive player in the MedTech landscape [5].

Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026RA'ANANA, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today reaffirmed its previously announced binding purchase orders totaling $49.5 million and provided an update on execution timing, noting that payment activity has been structured to commence with the 2026 fiscal c ...

Core Viewpoint - The article discusses the release of the procurement document for high-value medical consumables, specifically drug-coated balloons and urological intervention materials, by the National Organization for High-Value Medical Consumables Joint Procurement Office, outlining the requirements and timelines for the sixth batch of centralized procurement [4]. Group 1: Procurement Details - The procurement cycle will run from the effective date until December 31, 2028, with products needing to obtain valid medical device registration certificates by December 26, 2025 [4]. - The procurement covers two main categories: drug-coated balloons and urological intervention materials, with a total annual demand exceeding 3.4 million sets across 12 subcategories [4]. - The procurement will be implemented by the Tianjin Pharmaceutical Procurement Center, which will handle daily operations [4]. Group 2: Product Categories and Demand - The drug-coated balloon category includes four subcategories, with an annual demand of 690,000 units, where the coronary drug-coated balloon has the highest demand at 614,800 units [9]. - Major domestic companies such as Yinyi Biological, Lepu Medical, and Shenqi Medical lead in demand for coronary drug-coated balloons, with respective demands of 113,300, 97,100, and 86,900 units [9]. - The urological intervention category focuses on key surgical pathways, with an annual demand exceeding 2.75 million sets, where the ureteral intervention guide wire is the largest single item with a demand of 1,372,400 units [9]. Group 3: Market Share and Domestic Replacement - In the procurement, domestic companies account for approximately 80% of the market share for both coronary and peripheral drug-coated balloons, while foreign companies hold about 20% [10]. - The demand for ureteral intervention guide wires is also dominated by domestic products, indicating a trend towards accelerated domestic replacement [10]. - The introduction of the "anchor price" concept aims to rationalize prices and reduce vicious competition in the industry, benefiting more patients [7][19]. Group 4: Pricing and Competitive Rules - The procurement document introduces an "anchor price" based on the arithmetic average of the effective bidding prices of participating companies, set at 65% of the average price [19]. - The maximum effective bidding prices for various products have been established, with significant reductions compared to previous prices, such as the maximum effective bidding price for a non-target pressure measurement ureteral soft mirror being set at 1,860 yuan [11]. - The rules for selection and competition have been optimized, allowing non-selected companies to adjust their bids for a chance to qualify, which may enhance participation rates [20]. Group 5: Industry Impact - The changes in procurement rules are expected to reshape the competitive landscape, with leading domestic companies likely to benefit the most, while foreign companies may face pressure to localize [20]. - Smaller companies may exit the market, leading to increased industry concentration [22].

Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]